Envisagenics, Inc. announced that it has raised $25 million in a round of funding on June 4, 2024. The transaction included participation from returning investors New York City Economic Development Corporation, Third Kind Venture Capital, Red Cell Management, LLC, and new investor Bristol-Myers Squibb Company.